ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE
| Brand name | APADAZ |
|---|---|
| Active ingredient | ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE |
| Strength | 325MG;EQ 8.16MG BASE |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | January 2019 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 8461137 | February 2031 | substance, product |
| 9132125 | July 2030 | substance, product |
| 8828978 | July 2030 | product |
| 9549923 | July 2030 | substance, product |
| 8748413 | July 2030 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.